Across TCGA pan-cancer cohorts, MAFA Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MAFA data layer compared with 27 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher MAFA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAFA expression acts as an unfavorable survival marker.
SCLC are the cancer types where MAFA Mutation most reproducibly stratifies survival.